Ask a research question about Glaucoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Glaucoma
creation_date: '2025-12-18T17:01:35Z'
updated_date: '2026-04-22T20:13:21Z'
category: Complex
parents:
- Ophthalmological Disease
disease_term:
preferred_term: glaucoma
term:
id: MONDO:0005041
label: glaucoma
has_subtypes:
- name: Primary Open-Angle Glaucoma
description: Most common form, gradual onset with open drainage angle.
- name: Angle-Closure Glaucoma
description: Blocked drainage angle, can be acute or chronic.
- name: Normal-Tension Glaucoma
description: Optic nerve damage despite normal IOP.
- name: Secondary Glaucoma
description: Due to other conditions (trauma, steroids, uveitis).
pathophysiology:
- name: Elevated Intraocular Pressure
description: >
Impaired aqueous humor drainage through trabecular meshwork
leads to increased IOP in most cases. Elevated pressure damages
retinal ganglion cells and optic nerve.
locations:
- preferred_term: Anterior Chamber of Eye
term:
id: UBERON:0001766
label: anterior chamber of eyeball
biological_processes:
- preferred_term: Fluid Homeostasis
term:
id: GO:0050891
label: multicellular organismal-level water homeostasis
evidence:
- reference: PMID:26497784
reference_title: "Retinal ganglion cell apoptotic pathway in glaucoma: Initiating and downstream mechanisms."
supports: SUPPORT
snippet: "Elevated intraocular pressure and aging, the main risk factors for glaucoma, accelerate RGC apoptosis."
explanation: Identifies elevated IOP as a main risk factor that accelerates retinal ganglion cell apoptosis in glaucoma.
- name: Retinal Ganglion Cell Death
description: >
Progressive apoptosis of retinal ganglion cells leads to
irreversible vision loss. Mechanical stress, ischemia, and
excitotoxicity contribute to cell death.
locations:
- preferred_term: Retina
term:
id: UBERON:0000966
label: retina
cell_types:
- preferred_term: Retinal Ganglion Cell
term:
id: CL:0000740
label: retinal ganglion cell
biological_processes:
- preferred_term: Apoptosis
term:
id: GO:0006915
label: apoptotic process
evidence:
- reference: PMID:26497784
reference_title: "Retinal ganglion cell apoptotic pathway in glaucoma: Initiating and downstream mechanisms."
supports: SUPPORT
snippet: "Apoptosis of retinal ganglion cells (RGCs) in glaucoma causes progressive visual field loss, making it the primary cause of irreversible blindness worldwide."
explanation: Establishes that RGC apoptosis is the direct cause of visual field loss in glaucoma, confirming the central role of programmed cell death in disease pathogenesis.
- reference: PMID:26302410
reference_title: "Defects in autophagy caused by glaucoma-associated mutations in optineurin."
supports: SUPPORT
snippet: "A glaucoma-associated mutant of optineurin, E50K, impairs autophagy as well as vesicle trafficking, leading to death of retinal cells by apoptosis."
explanation: Links OPTN mutations to RGC apoptosis through impaired autophagy, providing a molecular mechanism for how genetic variants cause retinal ganglion cell death.
- reference: PMID:37542647
reference_title: "Anti-inflammatory Effects of Siponimod in a Mouse Model of Excitotoxicity-Induced Retinal Injury."
supports: PARTIAL
snippet: "Glaucoma is a leading cause of permanent blindness worldwide and is characterized by neurodegeneration linked to progressive retinal ganglion cell (RGC) death, axonal damage, and neuroinflammation."
explanation: Confirms that RGC death is a hallmark of glaucoma neurodegeneration and highlights the role of neuroinflammation in the degenerative process.
- name: Optic Nerve Degeneration
description: >
Loss of ganglion cell axons causes characteristic optic disc
cupping. Progressive nerve fiber layer loss detectable before
symptomatic visual field loss.
locations:
- preferred_term: Optic Nerve
term:
id: UBERON:0000941
label: cranial nerve II
- preferred_term: Optic Disc
term:
id: UBERON:0001783
label: optic disc
- name: Trabecular Meshwork Dysfunction
description: >
Age-related changes, oxidative stress, and altered extracellular
matrix reduce outflow facility. Increased resistance to aqueous
outflow.
locations:
- preferred_term: Trabecular Meshwork
term:
id: UBERON:0005969
label: eye trabecular meshwork
cell_types:
- preferred_term: Trabecular Meshwork Cell
term:
id: CL:0002367
label: trabecular meshwork cell
evidence:
- reference: PMID:10617907
reference_title: "The myocilin (MYOC) gene expression in the human trabecular meshwork."
supports: PARTIAL
snippet: "Myocilin gene is expressed clearly in the trabecular meshwork cells of both glaucomatous and nonglaucomatous eyes."
explanation: Confirms MYOC expression in trabecular meshwork cells, but expression alone only indirectly supports dysfunction.
- reference: PMID:37217093
reference_title: "Myocilin misfolding and glaucoma: A 20-year update."
supports: SUPPORT
snippet: "The prevailing pathogenic mechanism involves a gain of toxic function whereby mutant myocilin aggregates intracellularly instead of being secreted, which causes cell stress and an early timeline for TM cell death, elevated intraocular pressure, and subsequent glaucoma-associated retinal degeneration."
explanation: Describes how mutant myocilin causes trabecular meshwork cell death through intracellular aggregation, directly linking MYOC mutations to trabecular dysfunction and elevated IOP.
phenotypes:
- name: Visual Field Loss
category: Ophthalmological
frequency: VERY_FREQUENT
diagnostic: true
notes: Peripheral vision first
phenotype_term:
preferred_term: Visual Field Defect
term:
id: HP:0001123
label: Visual field defect
evidence:
- reference: PMID:26497784
reference_title: "Retinal ganglion cell apoptotic pathway in glaucoma: Initiating and downstream mechanisms."
supports: SUPPORT
snippet: "Apoptosis of retinal ganglion cells (RGCs) in glaucoma causes progressive visual field loss, making it the primary cause of irreversible blindness worldwide."
explanation: Directly links RGC apoptosis to progressive visual field loss, the cardinal clinical manifestation of glaucoma.
- name: Optic Disc Cupping
category: Ophthalmological
frequency: VERY_FREQUENT
diagnostic: true
phenotype_term:
preferred_term: Optic Atrophy
term:
id: HP:0000648
label: Optic atrophy
- name: Elevated Intraocular Pressure
category: Ophthalmological
frequency: FREQUENT
notes: Not present in normal-tension glaucoma
phenotype_term:
preferred_term: Elevated IOP
term:
id: HP:0012632
label: Abnormal intraocular pressure
evidence:
- reference: PMID:37217093
reference_title: "Myocilin misfolding and glaucoma: A 20-year update."
supports: SUPPORT
snippet: "The prevailing pathogenic mechanism involves a gain of toxic function whereby mutant myocilin aggregates intracellularly instead of being secreted, which causes cell stress and an early timeline for TM cell death, elevated intraocular pressure, and subsequent glaucoma-associated retinal degeneration."
explanation: Links mutant MYOC to elevated IOP through trabecular meshwork cell death, establishing the mechanistic connection between genetic mutations and the elevated pressure phenotype.
- name: Halos Around Lights
category: Ophthalmological
frequency: OCCASIONAL
notes: More common in angle-closure
phenotype_term:
preferred_term: Visual Impairment
term:
id: HP:0000505
label: Visual impairment
- name: Eye Pain
category: Ophthalmological
frequency: OCCASIONAL
notes: Acute angle-closure glaucoma
phenotype_term:
preferred_term: Eye Pain
term:
id: HP:0200026
label: Ocular pain
biochemical:
- name: Intraocular Pressure
presence: Elevated
context: "Greater than 21 mmHg in most cases"
genetic:
- name: MYOC
association: Causative
notes: Primary open-angle glaucoma
evidence:
- reference: PMID:37217093
reference_title: "Myocilin misfolding and glaucoma: A 20-year update."
supports: SUPPORT
snippet: "Mutations in the gene MYOC account for approximately 5% of cases of primary open angle glaucoma (POAG)."
explanation: Establishes MYOC as a causative gene for POAG, accounting for a significant proportion of cases.
- reference: PMID:37217093
reference_title: "Myocilin misfolding and glaucoma: A 20-year update."
supports: SUPPORT
snippet: "While myocilin is expressed in numerous tissues, mutant myocilin is only associated with disease in the anterior segment of the eye, in the trabecular meshwork."
explanation: Demonstrates tissue-specific pathogenicity of MYOC mutations in the trabecular meshwork of the eye.
- name: OPTN
association: Risk Factor
notes: Normal-tension glaucoma
evidence:
- reference: PMID:26302410
reference_title: "Defects in autophagy caused by glaucoma-associated mutations in optineurin."
supports: SUPPORT
snippet: "Certain mutations in optineurin (gene OPTN) are associated with primary open angle glaucoma."
explanation: Confirms OPTN mutations as a genetic risk factor for primary open angle glaucoma.
- reference: PMID:26302410
reference_title: "Defects in autophagy caused by glaucoma-associated mutations in optineurin."
supports: SUPPORT
snippet: "Thus, an optimum level of optineurin-mediated autophagy is crucial for survival of retinal cells, and impaired autophagy is likely to contribute to glaucoma pathogenesis."
explanation: Explains how OPTN variants contribute to glaucoma through dysregulated autophagy in retinal cells.
- name: WDR36
association: Risk Factor
- name: CAV1/CAV2
association: Risk Factor
environmental:
- name: Age
notes: Major risk factor, increases after 40
- name: Family History
notes: First-degree relatives at 4-9x increased risk
- name: African Ancestry
notes: Higher prevalence and severity
- name: Myopia
notes: Risk factor for open-angle glaucoma
- name: Corticosteroid Use
notes: Can induce steroid glaucoma
treatments:
- name: Prostaglandin Analogs
description: First-line topical drops that increase uveoscleral outflow.
context: First-line topical intraocular pressure-lowering therapy
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
qualifiers:
- predicate:
preferred_term: route of administration
term:
id: NCIT:C38114
label: Route of Administration
value:
preferred_term: topical route of administration
term:
id: NCIT:C38304
label: Topical Route of Administration
evidence:
- reference: PMID:8942890
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Purpose: To determine efficacy and safety of latanoprost, a prostaglandin analog for glaucoma, during 1 year of treatment."
explanation: This clinical trial directly supports prostaglandin analog therapy, using latanoprost as a representative first-line agent for glaucoma.
- reference: PMID:8942890
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Conclusion: Latanoprost safely and effectively reduces IOP for 1 year in patients of diverse nationalities, providing further evidence for its usefulness in chronic glaucoma therapy."
explanation: This provides direct human evidence that topical latanoprost produces sustained intraocular pressure lowering in glaucoma therapy.
- name: Beta-Blockers
description: Topical beta-blocker drops reduce aqueous humor production.
context: Alternative or adjunctive topical pressure-lowering therapy
treatment_term:
preferred_term: beta-blocker therapy
term:
id: MAXO:0000187
label: beta-adrenergic antagonist therapy
therapeutic_agent:
- preferred_term: timolol
term:
id: CHEBI:39465
label: timolol
qualifiers:
- predicate:
preferred_term: route of administration
term:
id: NCIT:C38114
label: Route of Administration
value:
preferred_term: topical route of administration
term:
id: NCIT:C38304
label: Topical Route of Administration
evidence:
- reference: PMID:16750466
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Objective: The objective of this study was to assess the hypotensive efficacy of timolol maleate 0.5%, brinzolamide 1%, or brimonidine tartrate 0.2% ophthalmic solution, administered in conjunction with travoprost 0.004%, in patients with primary open-angle laucoma (OAG) or ocular hypertension (OHT) whose intraocular pressure (IOP) did not meet the treatment target using travoprost 0.004% monotherapy."
explanation: This randomized study directly evaluates topical timolol as an intraocular pressure-lowering treatment in open-angle glaucoma or ocular hypertension.
- reference: PMID:16750466
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Conclusion: Brinzolamide 1% and timolol maleate 0.5% treatment were both associated with a significantly greater reduction in IOP compared with brimonidine 0.2% when administered as a nonfixed adjuvant to travoprost 0.004% in the treatment of patients with OAG and OHT whose IOP was inadequately controlled with travoprost monotherapy."
explanation: This supports timolol as an effective adjunctive topical beta-blocker therapy for additional pressure reduction.
- name: Alpha Agonists
description: Topical alpha-2 agonist drops reduce aqueous production and modestly increase outflow.
context: Adjunctive or alternative topical pressure-lowering therapy
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: brimonidine
term:
id: CHEBI:3175
label: brimonidine
qualifiers:
- predicate:
preferred_term: route of administration
term:
id: NCIT:C38114
label: Route of Administration
value:
preferred_term: topical route of administration
term:
id: NCIT:C38304
label: Topical Route of Administration
evidence:
- reference: PMID:14660453
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Methods: 16 newly diagnosed previously untreated glaucoma patients were randomly assigned to either timolol 0.5% or brimonidine 0.2%."
explanation: This randomized trial directly supports brimonidine as a therapeutic alpha agonist used in primary open-angle glaucoma.
- reference: PMID:14660453
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Results: IOP reduction was similar for both groups (p<0.05)."
explanation: This supports clinically meaningful intraocular pressure lowering with brimonidine in glaucoma treatment.
- name: Carbonic Anhydrase Inhibitors
description: Topical carbonic anhydrase inhibitors reduce aqueous humor production.
context: Adjunctive or alternative topical pressure-lowering therapy
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: dorzolamide
term:
id: CHEBI:4702
label: dorzolamide
- preferred_term: brinzolamide
term:
id: CHEBI:3176
label: brinzolamide
qualifiers:
- predicate:
preferred_term: route of administration
term:
id: NCIT:C38114
label: Route of Administration
value:
preferred_term: topical route of administration
term:
id: NCIT:C38304
label: Topical Route of Administration
evidence:
- reference: PMID:16750466
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Objective: The objective of this study was to assess the hypotensive efficacy of timolol maleate 0.5%, brinzolamide 1%, or brimonidine tartrate 0.2% ophthalmic solution, administered in conjunction with travoprost 0.004%, in patients with primary open-angle laucoma (OAG) or ocular hypertension (OHT) whose intraocular pressure (IOP) did not meet the treatment target using travoprost 0.004% monotherapy."
explanation: This randomized study directly evaluates brinzolamide, a topical carbonic anhydrase inhibitor, as an IOP-lowering therapy in glaucoma or ocular hypertension.
- reference: PMID:16750466
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Conclusion: Brinzolamide 1% and timolol maleate 0.5% treatment were both associated with a significantly greater reduction in IOP compared with brimonidine 0.2% when administered as a nonfixed adjuvant to travoprost 0.004% in the treatment of patients with OAG and OHT whose IOP was inadequately controlled with travoprost monotherapy."
explanation: This supports topical carbonic anhydrase inhibition, represented here by brinzolamide, as an effective adjunctive strategy for lowering intraocular pressure.
- name: Rho Kinase Inhibitors
description: Topical rho kinase inhibitors improve trabecular outflow and lower intraocular pressure.
context: Topical pharmacologic option for additional pressure lowering
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
qualifiers:
- predicate:
preferred_term: route of administration
term:
id: NCIT:C38114
label: Route of Administration
value:
preferred_term: topical route of administration
term:
id: NCIT:C38304
label: Topical Route of Administration
evidence:
- reference: PMID:29199013
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Purpose: To evaluate the efficacy and ocular and systemic safety of netarsudil 0.02% ophthalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with open-angle glaucoma and ocular hypertension."
explanation: This phase 3 clinical program directly supports rho kinase inhibitor therapy using netarsudil in open-angle glaucoma or ocular hypertension.
- reference: PMID:29199013
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Conclusions: In 2 large, randomized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma."
explanation: This supports netarsudil-based rho kinase inhibition as an effective and tolerated topical treatment option.
- name: Laser Trabeculoplasty
description: SLT increases trabecular outflow.
context: Drop-sparing procedural alternative to first-line medication
evidence:
- reference: PMID:30862377
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "At 36 months, 74·2% (95% CI 69·3-78·6) of patients in the selective laser trabeculoplasty group required no drops to maintain intraocular pressure at target."
explanation: This randomized trial supports selective laser trabeculoplasty as an effective drop-sparing treatment strategy in open-angle glaucoma or ocular hypertension.
- name: Trabeculectomy
description: Incisional filtration surgery for advanced or medically uncontrolled glaucoma.
context: Escalation therapy for advanced disease or inadequate control with drops
treatment_term:
preferred_term: trabeculectomy
term:
id: MAXO:0001082
label: trabeculectomy
evidence:
- reference: PMID:33980505
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Interventions: Mitomycin C augmented trabeculectomy (n=227) and escalating medical management with intraocular pressure reducing drops (n=226)"
explanation: This randomized trial directly evaluates trabeculectomy as a primary interventional treatment for advanced open-angle glaucoma.
- reference: PMID:33980505
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Conclusion: Primary trabeculectomy had similar quality of life and safety outcomes and achieved a lower intraocular pressure compared with primary medication."
explanation: This supports trabeculectomy as a clinically effective pressure-lowering option in advanced glaucoma.
- name: MIGS
description: Microstent-based and related minimally invasive glaucoma surgery options can reduce medication burden and improve pressure control.
context: Mild-to-moderate primary open-angle glaucoma, often combined with cataract surgery
evidence:
- reference: PMID:33166551
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Purpose: To report 3-year outcomes of the HORIZON study comparing cataract surgery (CS) with Hydrus Microstent (Ivantis, Inc) implantation versus CS alone."
explanation: This randomized trial directly studies a representative minimally invasive glaucoma surgery device in primary open-angle glaucoma.
- reference: PMID:33166551
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Conclusions: Combined CS and microstent placement for mild to moderate POAG is safe, more effective in lowering IOP with fewer medications, and less likely to result in further incisional glaucoma filtration surgery than CS alone at 3 years."
explanation: This supports MIGS as a pressure-lowering and medication-sparing surgical option in appropriately selected open-angle glaucoma.
classifications:
harrisons_chapter:
- classification_value: NEUROLOGIC
datasets:
references:
- reference: DOI:10.20944/preprints202512.0304.v1
title: 'Cell Motility Dynamics in Glaucoma: Mechanisms, Pathogenic Roles, and Therapeutic Targeting'
findings: []
- reference: DOI:10.3892/mmr.2025.13757
title: Research progress on molecular therapy for glaucoma (Review)
findings: []
- reference: DOI:10.7759/cureus.91633
title: 'Molecular Gatekeepers of Aqueous Outflow: From Mechanotransduction to Gene Therapy in Trabecular Meshwork Health and Disease'
findings: []
Disease Pathophysiology Research Report
Target Disease - Disease Name: Glaucoma - MONDO ID: MONDO_0005015 (primary open‑angle glaucoma falls under MONDO_0005015 hierarchy) - Category: Complex
Pathophysiology description (current understanding) Glaucoma comprises optic neuropathies characterized by retinal ganglion cell (RGC) degeneration and optic nerve head (ONH) remodeling. Elevated intraocular pressure (IOP) from impaired aqueous humor outflow via trabecular meshwork (TM) and Schlemm’s canal (SC) is a major risk driver; however, IOP‑independent mechanisms, including mitochondrial dysfunction, neuroinflammation, and genetic susceptibilities (e.g., OPTN/TBK1, SIX6) also contribute, particularly in normal‑tension glaucoma. A central theme emerging from recent work is a feed‑forward coupling of profibrotic TGF‑β signaling with mechanotransduction pathways (Hippo‑YAP/TAZ, integrin–FAK, TRPV4 and PIEZO1 channels) that stiffens TM/SC and ONH tissues, impairs cellular motility and adaptability, and elevates outflow resistance. Parallel mitochondrial and axonal transport stress in RGCs, and glial‑mediated neuroinflammation with inflammasome activation and blood‑retinal barrier (BRB) disruption, drive progressive axonopathy and vision loss (2023–2025 literature) (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15, wang2025researchprogresson pages 1-2).
1) Core pathophysiology - Dysregulated profibrotic signaling and mechanotransduction in the outflow tract: Elevated TGF‑β2 promotes ECM deposition (collagens, fibronectin), cytoskeletal stress fibers/CLANs, and EndMT in SC; downstream RhoA/ROCK and Hippo effectors YAP/TAZ link biochemical cues to stiffness and pro‑fibrotic transcription. Mechanosensitive channels TRPV4 and PIEZO1 transduce pressure/flow into Ca2+ signaling, contractility, and further ECM remodeling, generating a mechano‑biochemical feed‑forward loop that increases outflow resistance and IOP (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - Integrin–FAK focal adhesion signaling: Integrins (e.g., ITGA9) and FAK coordinate ECM–cytoskeleton coupling in TM/SC cells; aberrant activation aligns with tissue stiffness and impaired motility; ROCK inhibition can partly restore motility and outflow (rusciano2025cellmotilitydynamics pages 11-13, singh2025moleculargatekeepersof pages 2-3). - RGC mitochondrial dysfunction and axonopathy: High metabolic demand makes RGCs vulnerable to oxidative stress, disrupted oxidative phosphorylation, and mitophagy dysregulation; impaired axonal transport at the lamina cribrosa and energy failure contribute to early axon degeneration, progressing to soma loss (palanivel2025understandingtherole pages 30-34, wang2025researchprogresson pages 1-2). - Neuroinflammation and BRB dysfunction: Chronic activation of microglia and astrocytes, upregulation of cytokines (TNF‑α, IL‑1β), and inflammasome (e.g., NLRP3) involvement propagate neurodegeneration. BRB compromise amplifies leukocyte trafficking and inflammatory milieu at retina/ONH (palanivel2025understandingtherole pages 30-34, wang2025researchprogresson pages 1-2).
2) Key molecular players - Genes/Proteins: MYOC (mutant secretion defects → ER stress/UPR in TM and IOP elevation), OPTN and TBK1 (autophagy/mitophagy signaling and innate immunity; variants linked to NTG and RGC vulnerability), SIX6 (developmental transcription factor linked to optic nerve/RGC susceptibility), YAP1/TAZ (Hippo mechanotransduction), TGFB2 (profibrotic driver), TRPV4 and PIEZO1 (mechanosensitive channels), ITGA9/FAK (integrin–FAK adhesion signaling), NLRP3 (inflammasome) (palanivel2025understandingtherole pages 25-30, singh2025moleculargatekeepersof pages 2-3, wang2025researchprogresson pages 1-2, rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15, rusciano2025cellmotilitydynamics pages 6-7). - Chemical entities: ROCK inhibitors (cytoskeletal relaxation), agents modulating TGF‑β/ECM, antioxidants/mitochondrial support (e.g., nicotinamide discussed in 2023–2024 literature), emerging anti‑inflammatory strategies targeting inflammasome/cytokine axes (rusciano2025cellmotilitydynamics pages 13-15, wang2025researchprogresson pages 1-2). - Cell types: TM cells and SC endothelium (outflow resistance), astrocytes and lamina cribrosa fibroblasts at the ONH, microglia (neuroinflammation), RGCs (primary neuronal loss) (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, palanivel2025understandingtherole pages 30-34). - Anatomical locations: Trabecular meshwork (UBERON:0001772), Schlemm’s canal (UBERON:0001808), optic nerve head/lamina cribrosa (UBERON:0001801), retina (UBERON:0000966) (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 6-7).
3) Biological processes (GO) disrupted - ECM organization and fibrosis; EndMT/epithelial–mesenchymal transitions; mechanotransduction and response to mechanical stimulus; focal adhesion assembly and cytoskeletal organization; calcium ion transmembrane transport; ER stress and unfolded protein response; autophagy/mitophagy; inflammatory response and inflammasome activation; leukocyte adhesion and vascular responses (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, palanivel2025understandingtherole pages 25-30, wang2025researchprogresson pages 1-2).
4) Cellular components (sites of key processes) - Cell–ECM adhesions/focal adhesions (integrin–FAK complexes in TM/SC), plasma membrane mechanosensors (TRPV4/PIEZO1), nucleus (YAP/TAZ transcriptional co‑activators), ER (MYOC misfolding, UPR), mitochondria (RGC bioenergetics/mitophagy), extracellular space (ECM remodeling), tight junctions/inner BRB (endothelial/pericyte barriers) (singh2025moleculargatekeepersof pages 2-3, rusciano2025cellmotilitydynamics pages 6-7, wang2025researchprogresson pages 1-2, palanivel2025understandingtherole pages 30-34).
5) Disease progression sequence - Initiation in the outflow tract: TGF‑β2 elevation and mechanotransduction abnormalities in TM/SC promote ECM deposition, cytoskeletal stiffening, and reduced motility, increasing outflow resistance and IOP (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - Biomechanical stress at the ONH: Elevated IOP and scleral/laminar stiffness induce axoplasmic flow blockade and axonal injury; astrocyte reactivity and ECM remodeling further compromise axon bundles (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - Early RGC axonopathy to soma loss: Mitochondrial dysfunction and impaired transport precipitate distal axon degeneration, followed by RGC apoptosis/other death modes; microglial/astroglial activation and inflammasome signaling accelerate neurodegeneration (palanivel2025understandingtherole pages 30-34, wang2025researchprogresson pages 1-2). - IOP‑independent contributors: Genetic susceptibilities (OPTN/TBK1/SIX6) and vascular/neuroinflammatory factors drive disease even with normal tension, highlighting dual IOP‑dependent/independent components (wang2025researchprogresson pages 1-2, palanivel2025understandingtherole pages 25-30).
6) Phenotypic manifestations (clinical) - Structural: ONH cupping and lamina cribrosa remodeling; RNFL thinning; TM stiffening and reduced motion (advanced imaging) (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - Functional: Progressive visual field loss; reduced contrast sensitivity; electrophysiologic deficits linked to RGC dysfunction (wang2025researchprogresson pages 1-2).
Gene/protein annotations with ontology terms - HGNC: MYOC; GO: ER stress response, protein folding; CL: TM cell; UBERON: TM; Mechanism: ER stress/UPR with mutant MYOC; Evidence: Wang 2025 (review) (wang2025researchprogresson pages 1-2). - HGNC: OPTN; GO: selective autophagy, mitophagy; CL: RGC; UBERON: retina; Mechanism: autophagy dysfunction in NTG; Evidence: Wang 2025 (wang2025researchprogresson pages 1-2). - HGNC: TBK1; GO: regulation of autophagy/innate signaling; CL: microglia/RGC; UBERON: retina; Mechanism: OPTN–TBK1 axis; Evidence: Wang 2025 (wang2025researchprogresson pages 1-2). - HGNC: SIX6; GO: eye development; CL: retinal progenitors; UBERON: retina/ONH; Mechanism: developmental susceptibility; Evidence: Rusciano 2025 preprint review (rusciano2025cellmotilitydynamics pages 11-13). - HGNC: YAP1; GO: response to mechanical stimulus, transcription co‑activation; CL: TM/SC/astrocyte; UBERON: TM/ONH; Mechanism: Hippo–YAP/TAZ; Evidence: Rusciano 2025 (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13). - HGNC: TGFB2; GO: ECM organization, SMAD signaling; CL: TM/SC; UBERON: TM/SC; Mechanism: fibrosis and EndMT; Evidence: Rusciano 2025 (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13). - HGNC: PIEZO1; GO: mechanosensory ion channel activity; CL: SC endothelium; UBERON: SC; Mechanism: pressure/flow sensing; Evidence: Rusciano 2025 (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - HGNC: TRPV4; GO: calcium transport, cytoskeleton regulation; CL: TM; UBERON: TM; Mechanism: contractility and OHT; Evidence: Rusciano 2025 (rusciano2025cellmotilitydynamics pages 13-15). - HGNC: ITGA9/PTK2(FAK); GO: cell adhesion/focal adhesion; CL: TM/SC; UBERON: TM/SC; Mechanism: integrin–FAK; Evidence: Singh 2025 (singh2025moleculargatekeepersof pages 2-3). - HGNC: NLRP3; GO: inflammasome activation; CL: microglia; UBERON: retina/ONH; Mechanism: pyroptosis/neuroinflammation; Evidence: Wang 2025 (wang2025researchprogresson pages 1-2) and pathophysiology summaries (palanivel2025understandingtherole pages 30-34).
Cell type involvement (CL terms) - CL:0000740 retinal ganglion cell; CL:0000129 microglial cell; CL:0000746 astrocyte; TM cell (human ocular TM cell, commonly curated as ocular fibroblast-like cell); SC endothelial cell (venous/lymphatic-like endothelium) (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, palanivel2025understandingtherole pages 30-34).
Anatomical locations (UBERON terms) - UBERON:0001772 trabecular meshwork; UBERON:0001808 Schlemm’s canal; UBERON:0001801 optic nerve head; UBERON:0000966 retina (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13).
Chemical entities (CHEBI) and modalities - CHEBI: ROCK inhibitors (e.g., netarsudil class) to relax TM/SC cytoskeleton; anti‑fibrotics targeting TGF‑β/ECM; mitochondrial support (e.g., nicotinamide); emerging anti‑inflammatory/anti‑inflammasome approaches (rusciano2025cellmotilitydynamics pages 13-15, wang2025researchprogresson pages 1-2).
Evidence items (recent) - Mechanotransduction/fibrosis nexus and therapeutic implications (YAP/TAZ, TRPV4, PIEZO1; ROCK inhibition; diagnostic elastography): Rusciano 2025 preprint review (Dec 2025). URL: https://doi.org/10.20944/preprints202512.0304.v1 (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - TM mechanotransduction and gene therapy framing (integrin–FAK, TRPV4/PIEZO1; CRISPR prospects): Singh 2025 Cureus (Sep 2025). URL: https://doi.org/10.7759/cureus.91633 (singh2025moleculargatekeepersof pages 1-2, singh2025moleculargatekeepersof pages 2-3). - Mitochondrial dysfunction and multimodal cell‑death in RGCs; oxidative stress; molecular therapy directions: Wang 2025 Molecular Medicine Reports (Nov 2025). URL: https://doi.org/10.3892/mmr.2025.13757 (wang2025researchprogresson pages 1-2). - Neuroinflammation and inflammasome/BRB themes, with cytokines in glaucomatous milieu: Palanivel 2025 thesis review excerpts (2025) (palanivel2025understandingtherole pages 30-34, palanivel2025understandingtherole pages 25-30).
Current applications and real‑world implementations - IOP lowering remains standard of care; however, cytoskeletal modulators (ROCK inhibitors) directly target TM/SC mechanobiology and can reduce EndMT/fibrosis‑linked resistance; device‑based outflow restoration (MIGS) complements pharmacology; diagnostics increasingly assess TM stiffness/motion to stratify disease (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15, singh2025moleculargatekeepersof pages 2-3). - Gene therapy proof‑of‑concepts: CRISPR strategies against MYOC have preclinical efficacy in reducing ER‑stress–mediated TM dysfunction and IOP in transgenic models; these approaches seek durable correction beyond symptomatic pressure reduction (context discussed in reviews) (wang2025researchprogresson pages 1-2, singh2025moleculargatekeepersof pages 2-3). - Neuroprotection pipelines target mitochondrial resilience (e.g., nicotinamide) and modulate neuroinflammation (inflammasome/cytokines, microglial responses). Clinical translation requires biomarkers to identify IOP‑independent progression (wang2025researchprogresson pages 1-2, palanivel2025understandingtherole pages 30-34).
Expert opinions and analysis (authoritative perspectives) - Mechanobiology‑centered frameworks argue glaucoma reflects failure of tissue adaptability under chronic mechanical and biochemical stress, necessitating combined anti‑fibrotic, mechanotransduction‑targeting, and pressure‑lowering strategies; integration of OCT‑based elastography and AI may enable personalized, pre‑emptive treatment (Rusciano preprint 2025) (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15). - Molecular therapy reviews advocate tandem approaches: outflow repair (TM‑directed) plus RGC neuroprotection targeting mitochondria, oxidative stress, and programmed cell death pathways, particularly for normal‑tension disease (Wang 2025) (wang2025researchprogresson pages 1-2).
Relevant statistics and data - Genetic screening studies identify hypomorphic/rare variants across glaucoma genes (e.g., SIX6, OPTN, CYP1B1), supporting complex polygenic risk; multi‑ethnic GWAS have delineated IOP‑dependent and IOP‑independent components, aligning with clinical heterogeneity (summarized in 2025 review; additional 2024 studies cited therein) (wang2025researchprogresson pages 1-2).
Embedded ontology artifact | Gene/Protein (HGNC) | Key role in glaucoma (short) | GO Biological Process terms | Cell type (CL id/name) | Anatomy (UBERON id/name) | Pathway / Mechanism keywords | Evidence (DOI/URL + year) | |---|---|---|---|---|---|---| | MYOC | TM ECM homeostasis; mutant MYOC → ER stress, TM cell death, ↑IOP | protein folding; ER stress response; secretion | trabecular meshwork cell | UBERON:0001772 trabecular meshwork | ER stress, UPR, autophagy deregulation, TM fibrosis | https://doi.org/10.3892/mmr.2025.13757 (2025) (wang2025researchprogresson pages 1-2, palanivel2025understandingtherole pages 25-30) | | OPTN | Autophagy receptor; OPTN variants → RGC vulnerability (NTG) | selective autophagy; vesicle-mediated transport | CL:0000740 retinal ganglion cell | UBERON:0000966 retina | mitophagy/autophagy, protein aggregation, neuroinflammation | https://doi.org/10.3892/mmr.2025.13757 (2025) (palanivel2025understandingtherole pages 25-30, wang2025researchprogresson pages 1-2) | | TBK1 | Regulates autophagy and innate signaling; duplications linked to glaucoma | regulation of autophagy; innate immune signaling | microglial cell (CL:0000129) / RGCs | UBERON:0000966 retina | TBK1-OPTN autophagy axis, NF-κB signaling | https://doi.org/10.3892/mmr.2025.13757 (2025) (palanivel2025understandingtherole pages 25-30, wang2025researchprogresson pages 1-2) | | SIX6 | Developmental regulator; risk allele affects RGC development & susceptibility | eye development; regulation of transcription | retinal progenitor / RGC precursors | UBERON:0000966 retina | developmental susceptibility, CDKN2A/B network | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 11-13, palanivel2025understandingtherole pages 25-30) | | YAP1 (Hippo) | Mechanotransduction effector; mediates stiffness-induced TM/SC changes | regulation of transcription, response to mechanical stimulus | astrocyte (CL:0000746) / TM cells | UBERON:0001772 trabecular meshwork; UBERON:0001801 optic nerve head | Hippo–YAP/TAZ, mechanoresponsive transcription, fibrosis | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13) | | TGFB2 | Profibrotic cytokine elevated in AH; drives ECM deposition in TM/SC | extracellular matrix organization; SMAD signaling | trabecular meshwork cell / SC endothelium | UBERON:0001772 trabecular meshwork; UBERON:0001808 Schlemm's canal | TGF-β/SMAD, EndMT, ECM remodeling, fibrosis | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13) | | PIEZO1 | Mechanosensitive ion channel in SC/TM; links pressure to endothelial responses | response to mechanical stimulus; ion transport | Schlemm's canal endothelial cell | UBERON:0001808 Schlemm's canal | mechanotransduction, Ca2+ influx, ANGPT2–integrin loop | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15) | | TRPV4 | Mechanosensitive Ca2+ channel; mediates TM contractility and OHT | calcium ion transport; regulation of cytoskeleton | trabecular meshwork cell | UBERON:0001772 trabecular meshwork | TRPV4-mediated contractility, Ca2+ signaling, interaction with TGF-β | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 13-15, rusciano2025cellmotilitydynamics pages 11-13) | | ITGA9 / FAK (PTK2) | Integrin–FAK adhesion signaling; regulates TM/SC cell adhesion & remodeling | cell adhesion; focal adhesion assembly; signal transduction | endothelial / trabecular meshwork cell | UBERON:0001808 Schlemm's canal; UBERON:0001772 trabecular meshwork | integrin–FAK, mechanotransduction, ECM–cytoskeleton coupling | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 11-13, singh2025moleculargatekeepersof pages 2-3) | | NLRP3 | Inflammasome sensor driving retinal inflammation and pyroptosis | inflammasome activation; inflammatory response | microglial cell (CL:0000129) | UBERON:0000966 retina; UBERON:0001801 optic nerve head | NLRP3 inflammasome, IL-1β release, neuroinflammation | https://doi.org/10.3892/mmr.2025.13757 (2025) (palanivel2025understandingtherole pages 30-34, wang2025researchprogresson pages 1-2) | | LOXL1 | ECM crosslinking enzyme; linked to exfoliation and ECM stiffening | extracellular matrix organization; collagen fibril crosslinking | extracellular matrix / fibroblast-like TM cells | UBERON:0001772 trabecular meshwork | ECM crosslinking, increased stiffness, outflow resistance | https://doi.org/10.20944/preprints202512.0304.v1 (2025) (rusciano2025cellmotilitydynamics pages 11-13, palanivel2025understandingtherole pages 25-30) | | VCAM1 | Endothelial adhesion molecule; connects vascular inflammation to ONH injury | leukocyte adhesion; cell–cell adhesion | vascular endothelium / SC endothelium | UBERON:0001801 optic nerve head; UBERON:0001808 Schlemm's canal | endothelial activation, immune cell recruitment, vascular dysregulation | https://doi.org/10.7759/cureus.91633 (2025) (singh2025moleculargatekeepersof pages 2-3, wang2025researchprogresson pages 1-2) |
Table: Ontology-ready table mapping 12 key genes/proteins to their roles, GO processes, cell types (CL), anatomical sites (UBERON), core mechanisms, and recent evidence (DOIs/years) to support mechanistic curation for a disease knowledge base.
Limitations - Some mechanistic details derive from 2025 peer‑reviewed reviews and preprints synthesized from primary literature 2021–2024; where specific 2023–2024 clinical trials and numeric outcomes are requested, additional targeted database queries would refine statistics (rusciano2025cellmotilitydynamics pages 11-13, wang2025researchprogresson pages 1-2).
References with URLs and dates (selection) - Rusciano D, et al. Cell motility dynamics in glaucoma: mechanisms, pathogenic roles, and therapeutic targeting. Preprint. Dec 2025. https://doi.org/10.20944/preprints202512.0304.v1 (rusciano2025cellmotilitydynamics pages 6-7, rusciano2025cellmotilitydynamics pages 11-13, rusciano2025cellmotilitydynamics pages 13-15) - Singh P, et al. Molecular gatekeepers of aqueous outflow: from mechanotransduction to gene therapy. Cureus. Sep 2025. https://doi.org/10.7759/cureus.91633 (singh2025moleculargatekeepersof pages 1-2, singh2025moleculargatekeepersof pages 2-3) - Wang W, et al. Research progress on molecular therapy for glaucoma (Review). Mol Med Rep. Nov 2025. https://doi.org/10.3892/mmr.2025.13757 (wang2025researchprogresson pages 1-2) - Palanivel V. Understanding the role of neuropeptide Y in glaucoma. 2025. (Excerpts) (palanivel2025understandingtherole pages 30-34, palanivel2025understandingtherole pages 25-30)
References
(rusciano2025cellmotilitydynamics pages 6-7): Dario Rusciano, Caterina Gagliano, Alessandro Avitabile, and José Fernando Maya-Vetencourt. Cell motility dynamics in glaucoma: mechanisms, pathogenic roles, and therapeutic targeting. Unknown journal, Dec 2025. URL: https://doi.org/10.20944/preprints202512.0304.v1, doi:10.20944/preprints202512.0304.v1.
(rusciano2025cellmotilitydynamics pages 11-13): Dario Rusciano, Caterina Gagliano, Alessandro Avitabile, and José Fernando Maya-Vetencourt. Cell motility dynamics in glaucoma: mechanisms, pathogenic roles, and therapeutic targeting. Unknown journal, Dec 2025. URL: https://doi.org/10.20944/preprints202512.0304.v1, doi:10.20944/preprints202512.0304.v1.
(rusciano2025cellmotilitydynamics pages 13-15): Dario Rusciano, Caterina Gagliano, Alessandro Avitabile, and José Fernando Maya-Vetencourt. Cell motility dynamics in glaucoma: mechanisms, pathogenic roles, and therapeutic targeting. Unknown journal, Dec 2025. URL: https://doi.org/10.20944/preprints202512.0304.v1, doi:10.20944/preprints202512.0304.v1.
(wang2025researchprogresson pages 1-2): Weiwei Wang, Gangwei Cheng, Qi Zhou, Sheng Wang, and Linyi Zhang. Research progress on molecular therapy for glaucoma (review). Molecular Medicine Reports, 33:1-10, Nov 2025. URL: https://doi.org/10.3892/mmr.2025.13757, doi:10.3892/mmr.2025.13757. This article has 0 citations and is from a peer-reviewed journal.
(singh2025moleculargatekeepersof pages 2-3): Priti Singh, Samendra Karkhur, Vidhya Verma, Saroj Gupta, and Arushi Beri. Molecular gatekeepers of aqueous outflow: from mechanotransduction to gene therapy in trabecular meshwork health and disease. Cureus, Sep 2025. URL: https://doi.org/10.7759/cureus.91633, doi:10.7759/cureus.91633. This article has 1 citations and is from a poor quality or predatory journal.
(palanivel2025understandingtherole pages 30-34): V Palanivel. Understanding the role of neuropeptide y in ameliorating the degenerative changes in glaucoma. Unknown journal, 2025.
(palanivel2025understandingtherole pages 25-30): V Palanivel. Understanding the role of neuropeptide y in ameliorating the degenerative changes in glaucoma. Unknown journal, 2025.
(singh2025moleculargatekeepersof pages 1-2): Priti Singh, Samendra Karkhur, Vidhya Verma, Saroj Gupta, and Arushi Beri. Molecular gatekeepers of aqueous outflow: from mechanotransduction to gene therapy in trabecular meshwork health and disease. Cureus, Sep 2025. URL: https://doi.org/10.7759/cureus.91633, doi:10.7759/cureus.91633. This article has 1 citations and is from a poor quality or predatory journal.